CXCR5-Overexpressing Mesenchymal Stromal Cells Exhibit Enhanced Homing and Can Decrease Contact Hypersensitivity
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Mesenchymal stromal cells (MSCs) can modulate inflammation and contribute to tissue regeneration and, thus, have emerged as a promising option for cell-based therapy. However, the ability of MSCs to migrate to injured tissues still needs to be improved. In this study, we investigated whether genetically engineered MSCs could exhibit increased migratory properties and improved therapeutic efficacy. Using a mouse model of contact hypersensitivity (CHS), chemokine gene expression screening revealed that CXCL13 changed most significantly in injured tissue. Unfortunately, MSCs hardly express the corresponding receptor, CXCR5. Thus, CXCR5-overexpressing MSCs (MSC CXCR5 ) were generated that retained their abilities of proliferation, differentiation, and immunomodulation. Furthermore, MSC CXCR5 showed significantly increased migrating ability toward CXCL13. Importantly, systemic infusion of MSC CXCR5 dramatically suppressed CHS in mice, as evidenced by decreased levels of inflammatory cell infiltration and pro-inflammatory cytokine production. Numerous MSC CXCR5 migrated into inflamed ears, localized with T cells, inhibited T cell proliferation, promoted T cell apoptosis, and suppressed the production of T cell-derived pro-inflammatory factors. Collectively, these findings demonstrate that CXCR5 overexpression increases the ability of MSCs to respond to migratory stimuli and highly intensifies their immunomodulatory effects in vivo. This strategy for enhancing targeted stem/progenitor cell homing may improve the efficacy of MSC-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RHO GTPASES: Biochemistry and Biology
Jaffe, A. B., & Hall, A. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.020604.150721 · Cited by 3,009
Honczarenko, M., Le, Y., Swierkowski, M., Ghiran, I., Glodek, A. M., & Silberstein, L. E. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0319 · Cited by 722
Fonacier, L. S., Dreskin, S. C., & Leung, D. Y. M. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.039 · Cited by 139
Li, X., Xu, Z., Bai, J., Yang, S., Zhao, S., Zhang, Y., Chen, X., & Wang, Y. (2016) · Stem Cells International · doi:10.1155/2016/7495135 · Cited by 58
Self-citation
Cited by
Han, Y., Yang, J., Fang, J., Zhou, Y., Candi, E., Wang, J., Hua, D., Shao, C., & Shi, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00932-0 · Cited by 720
Self-citationChallenges and advances in clinical applications of mesenchymal stromal cells
Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01037-x · Cited by 712
“CXCR5-modified MSCs migrated to the damaged sites by binding to CXCL13, which was highly expressed in damaged tissues [79].”
BackgroundMesenchymal stem cell-based drug delivery strategy: from cells to biomimetic
Wu, H.-H., Zhou, Y., Tabata, Y., & Gao, J.-Q. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.019 · Cited by 288
Wang, J., Liu, X., Qiu, Y., Shi, Y., Cai, J., Wang, B., Wei, X., Ke, Q., Sui, X., Wang, Y., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0554-z · Cited by 268
Self-citationSrinivasan, A., Sathiyanathan, P., Yin, L., Liu, T. M., Lam, A., Ravikumar, M., Smith, R. A. A., Loh, H. P., Zhang, Y., Ling, L., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.11.009 · Cited by 44
Metadata
- Authors
- Zhang, X., Huang, W., Chen, X., Lian, Y., Wang, J., Cai, C., Huang, L., Wang, T., Ren, J., & Xiang, A. P.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 25
- Issue
- 6
- Pages
- 1434-1447
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2607568545
- Cited by
- 61
- References
- 4
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.